Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn
eGenesis is developing genome-engineered organs aimed at addressing the global shortage of transplantable organs and improving treatment options for patients suffering from organ failure.
· 8/25/2026, 12:56:17 PM· 2 min read
eGenesis is developing genome-engineered organs aimed at addressing the global shortage of transplantable organs and improving treatment options for patients suffering from organ failure.
Read original story →Related stories
business
Air India seeks $1.5 billion from owners Tata, Singapore Air as losses mount, sources say
business
Dr. Reddy’s CDMO arm Aurigene inks long-term manufacturing pact with global pharma major
business
Commodity costs, geopolitical tensions threaten to derail India Inc.’s Q2 earnings momentum: Brokerages
business